Related Experiment Videos
Carvedilol: a third-generation β-blocker should be a first-choice β-blocker
James J DiNicolantonio1, Daniel G Hackam
1Wegmans Pharmacy, 500 South Meadow Street, Ithaca, NY 14850, USA. jjdinicol@gmail.com
Expert Review of Cardiovascular Therapy
|December 14, 2011
Summary
This review highlights that carvedilol offers significant advantages over beta1-selective beta-blockers. Evidence suggests carvedilol should be a first-line treatment option for cardiovascular conditions.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are crucial in managing acute myocardial infarction, heart failure, and coronary events.
- Significant variations exist among beta-blockers regarding lipophilicity, metabolism, receptor binding, hemodynamics, and anti-inflammatory effects.
Purpose of the Study:
- To compare the properties and clinical outcomes of metoprolol, atenolol, and carvedilol.
- To present evidence supporting carvedilol as a preferred first-line beta-blocker.
Main Methods:
- Review of properties of metoprolol, atenolol, and carvedilol.
- Analysis of comparative experimental and clinical trials.
Main Results:
- Beta-blockers differ in key pharmacological and clinical properties.
- Carvedilol demonstrates distinct advantages over beta1-selective agents like metoprolol and atenolol.
Conclusions:
- The distinct properties of beta-blockers can influence patient outcomes.
- Carvedilol should be considered a first-line therapy due to its superior profile and demonstrated benefits.
Related Concept Videos
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...